Re-Defining Innovation in Pain Therapy: A Conversation with King's Management Team

King Pharmaceuticals is pursuing an interesting business model for pain therapy: driving abuse-resistance via continual innovation in formulation technology. It might be a home run in the current regulatory climate-provide King can stay on the right side of the regulators itself. We sat down with King CEO Brian Markison and Chief Scientist Eric Carter during the JP Morgan health care conference in January.